HIMS · Hims & Hers Health Inc
AI read · Neutral
The AI's read
HIMS topped Q2 revenue and adjusted EBITDA estimates and management raised full-year revenue guidance, while an analyst bumped the price target. The company cited GLP-1 demand and a renewed Novo partnership as drivers of reacceleration and international expansion. The market mildly sold off about 1.9% today, so buyers didn't cheer yet. RSI 23.82 labels the stock oversold, which creates upside skew versus the downside. We lean BULLISH because guidance upside plus the Novo tie give clear top-line runway, even with near-term reinvestment pain. Conviction 90% based on fresh, company-specific catalysts and favorable upside/downside asymmetry.